

Addition of Indole to Methyl 2-Chloro-2-cyclopropylideneacetate en Route to Spirocyclopropanated Analogues of Demethoxyfomitremorgine C and Tadalafil^[‡]

Michael Limbach,^[a] Suryakanta Dalai,^[a] André Janssen,^[a] Mazen Es-Sayed,^[b] Jörg Magull,^[c] and Armin de Meijere^{*[a]}

Keywords: Natural products / Peptidomimetics / Heterocycles / Small ring systems / Building blocks

Indole readily added across the double bond of the highly reactive Michael acceptor methyl 2-chloro-2-cyclopropylideneacetate (**4**) to yield 2-chloro-2-(3'-indolylcyclopropyl)acetate **5** (85%) which was converted in two steps into the racemic tryptophan analogue **7** in 90% yield. This in turn was transformed by a condensation and Pictet–Spengler sequence into the spirocyclopropane analogues, **11**, **13** and **15**,

of both the natural product (demethoxy)fomitremorgine C (**3b**, 3 steps, 11% yield) and the potent PDE-5 inhibitor Tadalafil (**2**, 3 steps, 71% yield) as well as the original lead structure with a hydantoin backbone (**1**, 2 steps, 79% yield).

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

Introduction

Lewis acid-catalyzed Michael addition of indoles onto Michael acceptors^[1] provides interesting 3-substituted tryptophan analogues^[2] and other indole derivatives.^[3] Condensation of these with various aldehydes and subsequent Pictet–Spengler reaction^[4] leads to 1-substituted tetrahydro- β -carboline, a common heterocyclic skeleton in many indole alkaloids and their analogues, mostly with interesting biological activities.^[5] Among these are the natural products demethoxyfomitremorgine C^[6] (**3b**) and fomitremorgine C (**3a**) (Figure 1), both neurotoxic secondary metabolites isolated from the fermentation broth of *Aspergillus fumigatus* BM 939^[7] that reverse multidrug resistance (MDR) which frequently occurs in cancer therapy,^[8] as well as selective inhibitors of cyclic guanosine monophosphate




Figure 1. Biologically active tetrahydro- β -carboline derivatives and their spirocyclopropanated analogues.

(cGMP) type 5 specific phosphodiesterase (PDE 5), such as the commercial drug Tadalafil (Elli Lilly).^[9]

In view of the fact that methyl 2-chloro-2-cyclopropylideneacetate (**4**) is a particularly reactive Michael acceptor and as such can favorably be employed as a building block for various conformationally restricted peptidomimetics,^[10] it was straightforward to conceive a facile access to cyclopropane analogues of the hydantoin lead structure to Tadalafil,^[11] Tadalafil itself,^[12] as well as demethoxyfomitremorgine C (Figure 1).^[13] We decided to execute this idea, not least because it was expected to demonstrate once again the enhanced tendency with which a suitable 1,1-disubstituted cyclopropane derivative undergoes ring closure due to an enforced favorable conformation just like the correspondingly substituted 2,2-disubstituted propane derivative.^[14]

[‡] Cyclopropyl Building Blocks for Organic Synthesis, 107. Part 106: F. Brackmann, D. S. Yufit, J. A. K. Howard, M. Es-Sayed, A. de Meijere, *Eur. J. Org. Chem.* **2005**, 600–609. Part 105: A. P. Molchanov, V. V. Diev, J. Magull, D. Vidovic, S. I. Kozhushkov, A. de Meijere, R. R. Kostikov, *Eur. J. Org. Chem.* **2005**, 593–599. Part 104: M. Schelper, A. de Meijere, *Eur. J. Org. Chem.* **2005**, 582–592.


[a] Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen, Germany
Fax: (internat.) +49-551-399475
E-mail: Armin.de.Meijere@chemie.uni-goettingen.de

[b] Bayer CropScience AG, Alfred-Nobel-Strasse 50, 40789 Monheim, Germany

[c] Institut für Anorganische Chemie, Georg-August-Universität Göttingen, Tammannstrasse 4, 37077 Göttingen, Germany

Results and Discussion

Indeed the potent Michael acceptor methyl 2-chloro-2-cyclopropylideneacetate (**4**), in the presence of ethylaluminum dichloride, rapidly underwent addition of indole to furnish **5** (85%). From here the cyclopropanated tryptophan methyl ester **7**^[15] was prepared in two simple steps (Scheme 1), namely by nucleophilic substitution of the chloride in **5** under phase-transfer catalysis with sodium azide in water and subsequent reduction of the azido ester **6** with tin(II) chloride (overall yield 90%).




Scheme 1. Pictet–Spengler reactions of some tryptophan analogues derived from the Michael adduct of indole with methyl 2-chloro-2-(cyclopropylidene)acetate; for more details see Table 1.

Condensation of **7** with *p*-anisaldehyde or piperonal in trimethyl orthoformate almost quantitatively yielded the corresponding imine, which upon treatment with 4 equiv. of trifluoroacetic acid at 0 °C and subsequent stirring at 20 °C gave the tetrahydro- β -carbolines **8** and **9** in 87 (*cis:trans* = 1:1.7) and 89% (1:2.5) yields, respectively. The diastereomers in both cases could be separated by simple crystallization from EtOAc (**8**) or EtOAc/diethyl ether (**9**) (Scheme 1, Table 1). The relative configurations of each of the diastereomers **9** were assigned by NOE experiments and were used as a basis for the assignment of the relative configurations of the diastereomers **8**.

Under the same conditions the imine formed from **7** and prenal underwent complete decomposition.^[16] An attempted cyclization by treatment with 20 equiv. of trifluoroacetic acid at –40 °C (0.2 M imine in CHCl₃) for 4 h according to a protocol of Bailey and co-workers^[17] only led to

complete recovery of the starting imine. However, at a slightly higher temperature and with a significantly extended reaction time (–30 °C, 63 h), tetrahydro- β -carboline **10** was obtained, albeit in only 36% yield. In this case only the *trans* diastereomer was isolated, whereas the corresponding non-cyclopropanated tetrahydro- β -carboline was reported to be formed predominantly as the *cis* diastereomer (6:1) with virtually the same moderate yield (36%).^[16]

Treatment of the tetrahydrocarbolines *trans*-**8** and *cis*-**8** with *n*-butyl isocyanate in refluxing ethyl methyl ketone for 12 h led directly to the hydantoin lead structures *trans*-**11** (91%) and *cis*-**11** (90% yield) (Scheme 2).



Scheme 2. Formation of the spirocyclopropanated hydantoin lead structures of Tadalafil and Tadalafil itself (**11** and **13**, respectively).


The tetrahydrocarboline derivatives *trans*-**9** and *cis*-**9** were acylated under Schotten–Baumann conditions with chloroacetyl chloride to provide the *N*-chloroacetyl derivatives *trans*-**12** (93%) and *cis*-**12** (81% yield), which upon reaction with methylamine in aqueous ethanol underwent nucleophilic substitution and subsequent ring-closing amide formation to give the spirocyclopropanated Tadalafil analogues *trans*-**13** (86%) and *cis*-**13** (81% yield).

Tabelle 1. Pictet–Spengler reactions of some tryptophan analogues derived from the Michael adduct of indole with methyl 2-chloro-2-cyclopropylideneacetate.

Compound	R	Conditions	Yield ^[a] [%]
8	<i>p</i> -MeO-C ₆ H ₄ -	TFA, CH ₂ Cl ₂ , 0 → 25 °C, 15 h	87 (1:1.7)
9	piperonyl	TFA, CH ₂ Cl ₂ , 0 → 25 °C, 12 h	89 (1:2.5)
10	prenyl	TFA, CH ₂ Cl ₂ , –30 °C, 63 h	36 (1:99)

^[a] The *cis/trans* diastereomeric ratio is given in parentheses.

To obtain the analogue of demethoxyfunitremorgine C, the tetrahydro- β -carboline **10** was condensed with Fmoc-(*S*)-Pro-Cl^[18] to yield the two diastereomers **14a** (46%) and **14b** (44% yield) which were separated by column chromatography, but not fully characterized owing to their dynamic NMR behavior even at an elevated temperature (90 °C). Removal of the Fmoc-protecting group by treatment with piperidine led directly to the diketopiperazine targets **15a** and **15b** in enantiopure form (Scheme 3). However, they are both diastereomers (opposite configuration at C-1 and C-3, respectively) of natural (demethoxy)funitremorgine C. The relative configuration of **15a** was proved by single-crystal X-ray structure analysis (Figure 2).^[19]



Scheme 3. Condensation of the tetrahydro- β -carboline **10** with Fmoc-(*S*)-Pro-Cl and ring closure to the diketopiperazine targets **15a** and **15b**.




Figure 2. Relative configuration of **15a** according to an X-ray crystal structure analysis.^[19]

Conclusions

In conclusion, addition of indole to methyl 2-chloro-2-cyclopropylideneacetate^[20] in the presence of a Lewis acid occurs with great facility and yields a 1,1-disubstituted cyclopropane derivative which is well suited for transformation to cyclopropanated tryptophan analogues. These undergo Pictet–Spengler annelation to tetrahydro- β -carboline derivatives with greater efficiency than the corresponding non-cyclopropanated precursors (87% for **8** versus 62%^[11] and 89% for **9** versus 61%^[12]). The products can readily be converted into spirocyclopropanated analogues of interest-

ing biologically active compounds by applying known methodology.

Experimental Section

General Remarks: All reagents were used as purchased from commercial suppliers without further purification. All reactions in non-aqueous solvents were carried out by using standard Schlenk techniques under dry nitrogen. Solvents were purified and dried according to conventional methods prior to use; diethyl ether (Et_2O) and tetrahydrofuran (THF) were freshly distilled from sodium/benzophenone. Solvents are abbreviated as follows: Py = pyridine, EtOAc = ethyl acetate, MEK = ethyl methyl ketone, MeOH = methanol, EtOH = ethanol. ^1H and ^{13}C NMR spectra were recorded at ambient temperature with a Bruker AM 250 instrument. Chemical shifts, δ , are given in ppm relative to solvent resonances (^1H : 7.26 ppm for chloroform; ^{13}C : 77.0 ppm for $[\text{D}]\text{chloroform}$), coupling constants, J , are given in Hertz. Characterization of the multiplicity of signals: s = singlet, br. s = broad singlet, d = doublet, t = triplet, m = multiplet. The multiplicities of the signals were determined by the DEPT technique: + = primary or tertiary (positive DEPT signal), – = secondary (negative DEPT signal), C_{quat} = quaternary carbon atoms. IR spectra were recorded with a Bruker IFS 66 spectrometer. Mass spectra were acquired on a Finnigan MAT 95 spectrometer. High-resolution mass spectra (HRMS) were obtained by preselected-ion peak matching at $R \approx 10000$ and are within ± 2 ppm of the exact mass. Chromatographic separations were carried out on Merck Silica 60 (0.063–0.200 mm, 70–230 mesh ASTM). The dimensions of the columns used are given as “diameter $\times$ height of the silica column”. TLC was performed with Machery–Nagel TLC Alugram® Sil G/UV₂₅₄ plates; detection was under UV light at 254 nm and development with ninhydrin (100 mg of ninhydrin, 3 mL of concd. acetic acid in 100 mL of 1-butanol) or MOPS reagent (10% molybdophosphoric acid in ethanol). Melting points were obtained with a Büchi Dr. Tottoli apparatus; values are uncorrected. Elemental analyses were carried out by the Mikroanalytisches Laboratorium des Instituts für Organische und Biomolekulare Chemie der Universität Göttingen.

Methyl 2-Chloro-2-[1-(1*H*-indol-3-yl)cyclopropyl]acetate (5**):** Ethylaluminum dichloride (51.0 mL, 51.0 mmol, 1 M solution in hexane) was added to a solution of methyl 2-chloro-2-cyclopropylideneacetate^[20] (4.40 g, 30.0 mmol) and indole (5.97 g, 51.0 mmol) in CH_2Cl_2 (150 mL) at 0 °C and the mixture was stirred at this temperature for 6 h. The mixture was carefully poured into an ice-cold saturated Na_2CO_3 solution (150 mL). Extraction of the aqueous phase with CH_2Cl_2 (3 $\times$ 200 mL), drying of the combined organic phases over MgSO_4 , evaporation of the solvents and chromatographic purification of the residue on 80 g of silica gel (4.5 $\times$ 20 cm, R_f = 0.45, pentane/ Et_2O , 5:1) yielded 6.70 g (85%) of **5** as a pale yellow oil. IR (film): $\tilde{\nu}$ = 3306, 3008, 2949, 1747, 1456, 1420, 1313, 1195, 1170, 1010 cm^{-1} . ^1H NMR (250 MHz, CDCl_3): δ = 1.02–1.24 (m, 3 H, Cpr-H), 1.35–1.46 (m, 1 H, Cpr-H), 3.60 (s, 3 H, OCH_3), 4.31 (s, 1 H, 2-H), 7.06–7.38 (m, 4 H, 2'-H, 5'-H, 6'-H, 7'-H), 7.65–7.72 (m, 1 H, 4'-H), 8.00–8.14 (br. s, 1 H, NH) ppm. ^{13}C NMR (62.9 MHz, CDCl_3 , DEPT): δ = 13.6 (–, Cpr-C), 21.6 (C_{quat} , Cpr-C), 52.8 (+, OCH_3), 69.2 (+, C-2), 111.4 (+, C-7'), 113.9 (C_{quat} , C-3'), 118.9 (+, C-4'*), 119.4 (+, C-6'*), 121.8 (+, C-5'), 125.8 (+, C-2'), 127.2 (C_{quat} , C-3a'), 135.7 (C_{quat} , C-7a'), 169.2 (C_{quat} , C=O) ppm. MS (70 eV): m/z (%) = 265/263 (14/52) [M^+], 228 (100) [$\text{M}^+ - \text{Cl}$], 196 (73), 168 (35), [$\text{M}^+ - \text{Cl} - \text{CO}_2\text{Me} - \text{H}$], 130 (29), 83 (28). $\text{C}_{14}\text{H}_{14}\text{ClNO}_2$ (263.7): calcd. 263.0713 (correct HRMS).

Methyl 2-Azido-2-[1-(1*H*-indol-3-yl)cyclopropyl]acetate (6): A suspension of **5** (6.50 g, 24.7 mmol), NaN₃ (4.80 g, 73.9 mmol) and Aliquat 336® (12.4 g, 12.4 mmol) in water (60 mL) was heated at 70 °C for 20 h. After cooling to 20 °C the reaction mixture was extracted with Et₂O (3 × 100 mL) and the combined organic phases were dried with Na₂SO₄. Removal of the solvent in vacuo and column chromatography of the residue on 80 g of silica gel (4.5 × 20 cm, *R_f* = 0.36, CH₂Cl₂/MeOH, 10:1) yielded 6.10 g (91%) of **6** as a slightly yellow oil. IR (KBr): $\tilde{\nu}$ = 3329, 2923, 2104, 1743, 1442, 1338, 1270, 1233, 1033, 746 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 1.00–1.18 (m, 3 H, Cpr-H), 1.24–1.42 (m, 1 H, Cpr-H), 3.68 (s, 3 H, OCH₃), 3.75 (s, 1 H, 2-H), 7.10–7.21 (m, 3 H, 2'-H, 5'-H, 6'-H), 7.33 (d, ³*J* = 7.5 Hz, 1 H, 7'-H), 7.70 (d, ³*J* = 7.5 Hz, 1 H, 4'-H), 8.00–8.14 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.9 (–, Cpr-C), 11.9 (–, Cpr-C), 20.1 (C_{quat}, Cpr-C), 52.4 (+, OCH₃), 69.2 (+, C-2), 111.4 (+, C-7'), 114.6 (C_{quat}, C-3'), 119.0 (+, C-4'*), 119.6 (+, C-6'*), 122.0 (+, C-5'), 125.3 (+, C-2'), 127.3 (C_{quat}, C-3a'), 135.8 (C_{quat}, C-7a'), 169.6 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 270 (71) [M⁺], 228 (100) [M⁺ – N₃], 196 (56), 183 (58) [M⁺ – N₂ – CO₂Me], 168 (20) [M⁺ – N₃ – CO₂Me – H], 156 (62), 129 (47), 117 (12). C₁₄H₁₄N₄O₂ (270.3): calcd. C 62.21, H 5.22; found C 62.12, H 5.33.

Methyl 2-Amino-2-[1-(1*H*-indol-3-yl)cyclopropyl]acetate (7): Tin(II) chloride dihydrate (9.90 g, 43.9 mmol) was added to a solution of **6** (6.00 g, 22.2 mmol) in MeOH (80 mL) and the solution was stirred at 20 °C for 18 h. After removal of the solvent in vacuo, the residue was taken up in CH₂Cl₂ (150 mL), the solution extracted with saturated Na₂CO₃ solution (100 mL), the aqueous layer re-extracted with CH₂Cl₂ (3 × 150 mL), the combined organic phases dried with MgSO₄, the solvents removed, and the residue purified by column chromatography on 100 g of silica gel (3 × 30 cm, *R_f* = 0.30, CH₂Cl₂/MeOH, 10:1) to yield 5.22 g (98%) of **7** as a pale yellow solid (m.p. 127 °C). IR (KBr): $\tilde{\nu}$ = 3348 (NH), 3136, 2986, 2945, 2919, 1736 (C=O), 1584, 1435, 1199, 1015, 919, 741 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.85–1.09 (m, 3 H, Cpr-H), 1.21–1.29 (m, 1 H, Cpr-H), 1.65 (s, 2 H, NH₂), 3.08 (s, 1 H, 2-H), 3.65 (s, 3 H, OCH₃), 7.07–7.20 (m, 3 H, 2'-H, 5'-H, 6'-H), 7.31 (d, ³*J* = 7.7 Hz, 1 H, 7'-H), 7.70 (d, ³*J* = 7.7 Hz, 1 H, 4'-H), 8.21–8.33 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 11.6 (–, Cpr-C), 12.2 (–, Cpr-C), 22.2 (C_{quat}, Cpr-C), 51.8 (+, OCH₃), 62.6 (+, C-2), 111.3 (+, C-7'), 115.3 (C_{quat}, C-3'), 119.3 (+, C-4'*), 119.5 (+, C-6'*), 122.0 (+, C-5'), 124.9 (+, C-2'), 127.8 (C_{quat}, C-3a'), 135.9 (C_{quat}, C-7a'), 174.7 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 244 (28) [M⁺], 215 (12), 185 (38) [M⁺ – CO₂Me], 168 (25), 156 (100), 129 (42), 117 (9). C₁₄H₁₆N₂O₂ (244.3): calcd. C 68.83, H 6.60; found C 68.65, H 6.84.

Methyl 1'-(4-Methoxyphenyl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-1*H*- β -carboline]-3'-carboxylate (8): *p*-Anisaldehyde (694 mg, 5.10 mmol) was added to a solution of **7** (1.22 g, 5.00 mmol) in trimethyl orthoformate (25 mL) and the solution was stirred at 20 °C for 8 h. After removal of the volatiles in vacuo and dissolving of the residue in CH₂Cl₂ (25 mL) at 0 °C trifluoroacetic acid (2.24 g, 19.6 mmol) was added over a period of 5 min, and the resulting red solution was stirred at 25 °C for 15 h. Dilution with saturated aqueous NaHCO₃ (20 mL), extraction of the aqueous phase with CH₂Cl₂ (2 × 25 mL), washing of the combined organic phases with brine (50 mL), drying over MgSO₄ and column chromatography of the residue on 50 g of silica gel (3 × 15 cm, *R_f* = 0.54, Et₂O) yielded 1.57 g (87%) of crude **8** as a mixture of *cis* and *trans* diastereomers (1:1.7). Crystallization from EtOAc yielded the *trans* diastereomer (830 mg, 46%) as a colorless solid, m.p. 190 °C. The residue from the mother liquor contained the *cis* and *trans*

diastereomers in a ratio of 5:1, m.p. 91–98 °C. **trans-8**: IR (KBr): $\tilde{\nu}$ = 3393, 3171, 2956, 1725, 1514, 1246, 1178, 1027 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 1.06–1.12 (m, 2 H, Cpr-H), 1.4–1.48 (m, 1 H, Cpr-H), 1.80–1.88 (m, 1 H, Cpr-H), 2.20–2.81 (br. s, 1 H, NH), 3.44 (s, 1 H, CH), 3.70 (s, 3 H, OCH₃), 3.82 (s, 3 H, OCH₃), 5.52 (s, 1 H, CH), 6.84–6.90 (m, 2 H, aryl-H), 6.94–7.12 (m, 2 H, aryl-H), 7.16–7.42 (m, 4 H, aryl-H), 7.55 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.7 (–, Cpr-C), 13.6 (–, Cpr-C), 20.0 (C_{quat}, Cpr-C), 51.8 (+, OCH₃), 54.2 (+, OCH₃), 55.3 (+, CH), 62.2 (+, CH), 111.2 (+, aryl-C), 111.5 (C_{quat}, aryl-C), 114.1 (+, 2 C, aryl-C), 118.8 (+, aryl-C), 119.3 (+, aryl-C), 121.4 (+, aryl-C), 124.5 (C_{quat}, aryl-C), 130.0 (+, 2 C, aryl-C), 133.3 (C_{quat}, aryl-C), 134.8 (C_{quat}, aryl-C), 136.0 (C_{quat}, aryl-C), 159.5 (C_{quat}, aryl-C), 172.7 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 362 (100) [M⁺], 303 (75) [M⁺ – CO₂Me], 195 (50), 168 (18), 121 (22). C₂₂H₂₂N₂O₃ (362.4): calcd. C 72.91, H 6.12, N 7.73; found C 72.83, H 6.05, N 7.58. **cis-8**: IR (KBr): $\tilde{\nu}$ = 3394, 3004, 2950, 1734, 1512, 1457, 1251, 1174, 1030 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.86–0.91 (m, 1 H, Cpr-H), 1.04–1.40 (m, 2 H, Cpr-H), 1.68–1.80 (m, 1 H, Cpr-H), 2.21–2.80 (br. s, 1 H, NH), 3.46 (s, 1 H, CH), 3.74 (s, 3 H, OCH₃), 3.84 (s, 3 H, OCH₃), 5.23 (s, 1 H, CH), 6.84–6.92 (m, 2 H, aryl-H), 6.94–7.12 (m, 2 H, aryl-H), 7.16–7.42 (m, 4 H, aryl-H), 7.52 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 9.0 (–, Cpr-C), 11.8 (–, Cpr-C), 20.2 (C_{quat}, Cpr-C), 51.8 (+, OCH₃), 55.3 (+, CH), 57.1 (+, OCH₃), 62.5 (+, CH), 111.3 (+, aryl-C), 113.4 (C_{quat}, aryl-C), 114.3 (+, 2 C, aryl-C), 118.8 (+, aryl-C), 119.5 (+, aryl-C), 121.6 (+, aryl-C), 124.5 (C_{quat}, aryl-C), 129.8 (+, 2 C, aryl-C), 132.1 (C_{quat}, aryl-C), 135.9 (C_{quat}, aryl-C), 159.7 (C_{quat}, aryl-C), 170.9 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 363/362 (20/100) [M⁺], 303 (75) [M⁺ – CO₂Me], 302 (35), 195 (50), 168 (18), 121 (22). C₂₂H₂₂N₂O₃ (362.4): calcd. C 72.91, H 6.12, N 7.73; found C 72.49, H 5.98, N 7.61.

trans-2'-Butyl-10'-(4-methoxyphenyl)-3a',4',9',10'-tetrahydrospiro[cyclopropane-1,4'-(2',9',11'-triazacyclopenta[*b*]fluorene)]-1',3'-dione (trans-11): *n*-Butyl isocyanate (31 mg, 313 μ mol) was added to a solution of **trans-8** (100 mg, 276 μ mol) in MEK (5 mL) and the mixture was stirred at 80 °C for 12 h. The solvent was removed in vacuo, and the residue purified by chromatography on 15 g of silica (3 × 15 cm, *R_f* = 0.35, pentane/Et₂O, 1:1) to yield 108 mg (91%) of **trans-11** as a colorless solid, m.p. 178 °C. IR (KBr): $\tilde{\nu}$ = 3309, 2959, 2933, 2866, 1761, 1708, 1512, 1457, 1249, 1174, 1078 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.92 (t, ³*J* = 8 Hz, 3 H, CH₃), 1.08–1.42 (m, 4 H, Cpr-H), 1.55–1.62 (m, 3 H, CH₂), 1.92–2.04 (m, 1 H, CH₂), 3.40–3.52 (m, 2 H, NCH₂), 3.77 (s, 3 H, OCH₃), 4.48 (s, 1 H, CH), 6.3 (s, 1 H, CH), 6.80–6.91 (m, 2 H, aryl-H), 7.04–7.5 (m, 6 H, aryl-H), 8.04 (br. s, 1 H, NH) ppm. ¹³C NMR (50.3 MHz, CDCl₃, APT): δ = 7.8 ppm (–, Cpr-C), 11.7 (–, Cpr-C), 13.6 (+, CH₃), 18.9 (–, CH₂), 19.9 (–, Cpr-C), 30.1 (–, CH₂), 38.5 (–, NCH₂), 51.1 (+, OCH₃), 55.3 (+, CH), 56.4 (+, CH), 111.5 (+, aryl-C), 113.3 (+, aryl-C), 114.4 (+, 2 C, aryl-C), 119.0 (+, aryl-C), 120.0 (+, aryl-C), 122.4 (+, aryl-C), 123.9 (–, aryl-C), 129.6 (+, 2 C, aryl-C), 131.1 (–, aryl-C), 131.4 (–, aryl-C), 136.8 (–, aryl-C), 154.7 (–, aryl-C), 159.9 (–, C=O), 170.0 (–, C=O) ppm. MS (70 eV): *m/z* (%) = 430/429 (30/100) [M⁺], 322 (35), 301 (10), 195 (10). C₂₆H₂₇N₃O₃ (429.5): calcd. C 72.71, H 6.34, N 9.78; found C 72.57, H 6.32, N 9.57.

cis-2'-Butyl-10'-(4-methoxyphenyl)-3a',4',9',10'-tetrahydrospiro[cyclopropane-1,4'-(2',9',11'-triazacyclopenta[*b*]fluorene)]-1',3'-dione (cis-11): *n*-Butyl isocyanate (158 mg, 1.60 mmol) was added to a solution of **8** (480 mg, 1.33 mmol, *cis:trans* = 5:1) in MEK (20 mL) and the mixture was stirred at 80 °C for 12 h. Evap-

oration of the solvents and chromatographic purification of the residue on 20 g of silica (3×15 cm, pentane/Et₂O, 1:2) yielded 84 mg (89% from the starting *trans* diastereomer) of *trans*-**11** (R_f = 0.71) and 426 mg (90%) of *cis*-**11** (R_f = 0.30), the latter as a colorless solid, m.p. 104–105 °C. IR (KBr): $\tilde{\nu}$ = 3290, 2961 2933, 2871, 1766, 1702, 1512, 1447, 1331, 1244, 1173, 1063 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.90 (t, ³J = 8 Hz, 3 H, CH₃), 1.12–1.38 (m, 4 H), 1.55–1.62 (m, 2 H, CH₂), 1.85–2.04 (m, 2 H, CH₂), 3.40–3.52 (m, 2 H, NCH₂), 3.80 (s, 3 H, OCH₃), 4.65 (s, 1 H, CH), 5.84 (s, 1 H, CH), 6.85–6.91 (m, 2 H, aryl-H), 7.04–7.36 (m, 6 H, aryl-H), 7.52 (br. s, 2 H, aryl-H) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 7.1 (–, Cpr-C), 11.0 (–, Cpr-C), 13.6 (+, CH₃), 18.9 (–, CH₂), 19.9 (C_{quat}, Cpr-C), 30.0 (–, CH₂), 38.3 (–, NCH₂), 55.1 (+, OCH₃), 56.3 (+, CH), 60.5 (+, CH), 111.4 (+, aryl-C), 112.0 (C_{quat}, aryl-C), 114.1 (+, 2 C, aryl-C), 119.0 (+, aryl-C), 119.9 (+, aryl-C), 122.2 (+, aryl-C), 124.0 (C_{quat}, aryl-C), 129.1 (+, 2 C, aryl-C), 130.7 (C_{quat}, aryl-C), 134.3 (C_{quat}, aryl-C), 136.9 (C_{quat}, aryl-C), 154.7 (C_{quat}, aryl-C), 159.5 (C_{quat}, C=O), 169.1 (C_{quat}, C=O) ppm. MS (70 eV): m/z (%) = 430/429 (30/100) [M⁺], 322 (38), 301 (10), 223 (10) 195 (10). C₂₆H₂₇N₃O₃ (429.5): calcd. C 72.71, H 6.34, N 9.78; found C 72.45, H 6.29, N 9.81.

Methyl 1'-(1,3-Benzodioxol-5-yl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-(1H- β -carboline)]-3'-carboxylate (9): Piperonal (750 mg, 5.00 mmol) was added to a solution of **7** (1.22 g, 5.00 mmol) in trimethyl orthoformate (25 mL) and the solution was stirred at 25 °C for 8 h. After removal of the volatiles in vacuo the residue was taken up in CH₂Cl₂ (30 mL), at 0 °C trifluoroacetic acid (2.28 g, 20.0 mmol) was added over a period of 5 min and the solution was stirred at 25 °C for 12 h. Dilution with CH₂Cl₂ (50 mL), addition of saturated aqueous NaHCO₃ (25 mL), extraction of the aqueous phase with CH₂Cl₂ (2 $\times$ 30 mL), drying of the combined organic phases over MgSO₄, evaporation of the solvents and column chromatography of the residue on 50 g of silica gel (3 $\times$ 15 cm, R_f = 0.40, pentane/Et₂O, 2:1) yielded 1.67 g (89%) of crude **9** as a mixture of the *cis* and *trans* diastereomers (1:2.5). Crystallization from EtOAc/pentane yielded the *trans* diastereomer (980 mg, 52%) as a colorless solid, m.p. 190 °C. The residue from the mother liquor contained the *cis* and *trans* diastereomers in a ratio of 3:1, m.p. 79–85 °C. *trans*-**9**: IR (KBr): $\tilde{\nu}$ = 3271, 2972, 2892, 1740, 1487, 1354, 1238, 1111, 1038 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 1.06–1.12 (m, 2 H, Cpr-H), 1.38–1.42 (m, 1 H, Cpr-H), 1.80–1.82 (m, 1 H, Cpr-H), 2.20 (br. s, 1 H, NH), 3.42 (s, 1 H, CH), 3.71 (s, 3 H, OCH₃), 5.61 (s, 1 H, CH), 5.94 (s, 2 H, CH₂), 6.72–6.92 (m, 3 H, aryl-H), 6.96–7.14 (m, 2 H, aryl-H), 7.18–7.38 (m, 2 H, aryl-H), 7.60 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.7 (–, Cpr-C), 13.6 (–, Cpr-C), 15.2 (C_{quat}, Cpr-C), 51.7 (+, CH₃), 54.6 (+, CH), 62.3 (+, CH), 101.1 (–, CH₂), 108.1 (+, aryl-C), 108.9 (+, aryl-C), 111.2 (+, aryl-C), 111.5 (C_{quat}, aryl-C), 118.8 (+, aryl-C), 119.4 (+, aryl-C), 121.4 (+, aryl-C), 122.0 (+, aryl-C), 124.5 (C_{quat}, aryl-C), 134.3 (C_{quat}, aryl-C), 135.5 (C_{quat}, aryl-C), 136.1 (C_{quat}, aryl-C), 147.5 (C_{quat}, aryl-C), 148.0 (C_{quat}, aryl-C), 172.9 (C_{quat}, C=O) ppm. MS (70 eV): m/z (%) = 376 (100) [M⁺], 359 (20), 317 (64) [M⁺ – CO₂Me], 195 (10), 168 (18). C₂₂H₂₀N₂O₄ (376.4): calcd. C 70.20, H 5.36, N 7.44; found C 69.90, H 5.60, N 7.55. *cis*-**9**: IR (KBr): $\tilde{\nu}$ = 3302, 3013, 2890, 2773, 1735, 1697, 1487, 1443, 1248, 1039 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.85–0.92 (m, 1 H, Cpr-H), 1.38–1.42 (m, 2 H, Cpr-H), 1.72–1.80 (m, 1 H, Cpr-H), 3.10 (br. s, 1 H, NH), 3.75 (s, 3 H, CH₃), 4.28 (s, 1 H, CH), 5.20 (s, 1 H, CH), 5.96 (s, 2 H, CH₂), 6.72–6.94 (m, 3 H, aryl-H), 6.98–7.14 (m, 2 H, aryl-H), 7.18–7.38 (m, 2 H, aryl-H), 7.55 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.7 (–, Cpr-C), 13.6 (–, Cpr-C), 20.0 (C_{quat}, Cpr-C), 51.8 (+, CH₃), 54.2 (+, CH),

62.2 (+, CH), 101.4 (–, CH₂), 108.2 (+, aryl-C), 111.2 (+, aryl-C), 111.5 (C_{quat}, aryl-C), 114.1 (+, aryl-C), 118.8 (+, aryl-C), 119.3 (+, aryl-C), 121.4 (+, aryl-C), 124.5 (C_{quat}, aryl-C), 130.0 (+, aryl-C), 133.3 (C_{quat}, aryl-C), 134.2 (C_{quat}, aryl-C), 134.8 (C_{quat}, aryl-C), 136.0 (C_{quat}, aryl-C), 159.5 (C_{quat}, aryl-C), 172.7 (C_{quat}, C=O) ppm. MS (70 eV): m/z (%) = 376 (100) [M⁺], 359 (20), 317 (64) [M⁺ – CO₂Me], 315 (20), 289 (12), 195 (10), 168 (18). C₂₂H₂₀N₂O₄ (376.4): calcd. C 70.20, H 5.36, N 7.44; found C 70.48, H 5.56, N 7.13.

Methyl trans-1'-(1,3-Benzodioxol-5-yl)-2'-(2-chloroacetyl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-(1H- β -carboline)]-3'-carboxylate (*trans*-12**):** Chloroacetyl chloride (372 mg, 3.30 mmol) was added to a mixture of *trans*-**9** (619 mg, 1.65 mmol) and 1 N Na₂CO₃ (8.25 mL, 8.25 mmol) in CH₂Cl₂ (30 mL) at 0 °C, the mixture was stirred at 20 °C for 2 h, diluted with CH₂Cl₂ (25 mL) and washed with a saturated NaHCO₃ solution (20 mL). Drying over MgSO₄, evaporation of the solvents and chromatographic purification of the residue on 25 g of silica (1.5 $\times$ 20 cm, R_f = 0.40, pentane/Et₂O, 1:2) yielded 697 mg (93%) of *trans*-**12** as a colorless solid, m.p. 118 °C. IR (KBr): $\tilde{\nu}$ = 3302, 2890, 1739, 1662, 1487, 1444, 1394, 1240, 1039 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 1.06–1.12 (m, 1 H, Cpr-H), 1.24–1.30 (m, 1 H, Cpr-H), 1.52–1.64 (m, 1 H, Cpr-H), 2.18–2.26 (m, 1 H, Cpr-H), 3.65 (s, 3 H, OCH₃), 3.74–4.15 (m, 3 H, CH₂,CH), 5.81–5.93 (m, 2 H, CH₂), 6.12 (s, 1 H, CH), 6.72–6.80 (m, 1 H, aryl-H), 6.86–7.00 (m, 2 H, aryl-H), 7.02–7.28 (m, 3 H, aryl-H), 7.40–7.51 (m, 1 H, aryl-H), 8.60 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.3 (–, Cpr-C), 15.3 (–, Cpr-C), 19.5 (C_{quat}, Cpr-C), 43.1 (–, CH₂), 52.8 (+, OCH₃), 57.6 (+, CH), 62.2 (+, CH), 101.2 (–, CH₂), 106.4 (C_{quat}, aryl-C), 107.3 (+, aryl-C), 108.6 (+, aryl-C), 111.5 (+, aryl-C), 118.4 (+, aryl-C), 118.8 (C_{quat}, aryl-C), 119.3 (+, aryl-C), 121.4 (+, aryl-C), 124.5 (+, aryl-C), 135.0 (C_{quat}, 2 C, aryl-C), 136.2 (C_{quat}, 2 C, aryl-C), 149.2 (C_{quat}, aryl-C), 169.4 (C_{quat}, C=O), 171.8 (C_{quat}, C=O) ppm. MS (70 eV): m/z (%) = 454/452 (22/63) [M⁺], 417 (36) [M⁺ – Cl], 375 (100) [M⁺ – COCH₂Cl], 315 (40), 195 (20). C₂₄H₂₁ClN₂O₅ (452.9): calcd. C 63.65, H 4.67, N 6.19; found C 63.82, H 4.92, N 5.96.

Methyl cis-1'-(1,3-Benzodioxol-5-yl)-2'-(2-chloroacetyl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-(1H- β -carboline)]-3'-carboxylate (*cis*-12**):** Chloroacetyl chloride (452 mg, 4.00 mmol) was added to a mixture of *cis*-**9** (752 mg, 2.00 mmol, mixture of *cis/trans* = 3:1) and 1 N Na₂CO₃ (10.0 mL, 10.0 mmol) in CH₂Cl₂ (25 mL) at 0 °C, the mixture was stirred at 20 °C for 2 h, diluted with CH₂Cl₂ (25 mL) and washed with saturated NaHCO₃ solution (20 mL). Drying over MgSO₄, evaporation of the solvents and chromatographic purification on 25 g of silica (1.5 $\times$ 20 cm, R_f = 0.51, pentane/Et₂O, 1:1) yielded 551 mg (81% from pure *cis*-**9**) of *cis*-**12** as a colorless solid, m.p. 125–132 °C. IR (KBr): $\tilde{\nu}$ = 3295, 2891, 1738, 1670, 1486, 1395, 1040 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): δ = 0.86–0.92 (m, 1 H, Cpr-H), 0.96–1.15 (m, 1 H, Cpr-H), 1.42–1.58 (m, 1 H, Cpr-H), 2.05–2.21 (m, 1 H, Cpr-H), 3.58 (s, 3 H, OCH₃), 3.92–4.10 (m, 3 H, CH₂,CH), 5.78–5.95 (m, 2 H, CH₂), 6.08 (s, 1 H, CH), 6.63–6.76 (m, 1 H, aryl-H), 6.82–7.13 (m, 4 H, aryl-H), 7.21–7.40 (m, 2 H, aryl-H), 7.82 (br. s, 1 H, NH) ppm. ¹³C NMR (50.3 MHz, CDCl₃, APT): δ = 10.2 (–, Cpr-C), 15.1 (–, Cpr-C), 19.6 (–, Cpr-C), 43.3 (–, CH₂), 52.7 (+, OCH₃), 57.7 (+, CH), 64.1 (+, CH), 101.3 (–, CH₂), 106.4 (–, aryl-C), 108.7 (+, aryl-C), 107.4 (+, aryl-C), 111.4 (+, aryl-C), 118.8 (–, aryl-C), 119.2 (–, aryl-C), 119.8 (+, aryl-C), 122.1 (+, aryl-C), 124.2 (+, aryl-C), 136.3 (–, 2 C, aryl-C), 136.8 (–, 2 C, aryl-C), 147.5 (–, aryl-C), 166.2 (–, C=O), 171.5 (–, C=O) ppm. MS (70 eV): m/z (%) = 454/452 (30/79) [M⁺], 417 (48) [M⁺ – Cl], 375 (100) [M⁺

– COCH₂Cl], 315 (46), 195 (20). C₂₄H₂₁ClN₂O₅ (452.9): calcd. C 63.65, H 4.67, N 6.19; found C 63.90, H 5.31, N 6.16.

trans-6'-(1,3-Benzodioxol-5-yl)-2'-methyl-2',3',6',7',12',12a'-hexahydrospiro[cyclopropane-1,12'-pyrazino[1',2':1,6]pyrido[3,4-b]indole]1',4'-dione (trans-13): A solution of *trans*-12 (596 mg, 1.32 mmol) and methylamine (1 mL, 40% in H₂O) in EtOH (25 mL) was heated at 75 °C for 16 h. All volatiles were removed in vacuo, the residue was dissolved in CH₂Cl₂ (30 mL), the solution washed with water (20 mL) and dried with MgSO₄. Evaporation of the solvent and chromatographic purification of the residue on 25 g of silica (1.5 × 20 cm, R_f = 0.23, pentane/Et₂O, 1:2) yielded 470 mg (86%) of *trans*-13 as a colorless solid, m.p. > 250 °C. IR (KBr): $\tilde{\nu}$ = 3299, 2888, 1664, 1488, 1330, 1236, 1036, 935 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.70–0.78 (m, 1 H, Cpr-H), 1.24–1.32 (m, 1 H, Cpr-H), 1.54–1.82 (m, 2 H, Cpr-H), 2.98 (s, 3 H, CH₃), 3.86–4.20 (m, 2 H, CH₂), 4.56 (s, 1 H, CH), 5.32 (s, 1 H, CH), 5.95 (s, 2 H, CH₂), 6.68–6.82 (m, 3 H, aryl-H), 6.96–7.20 (m, 2 H, aryl-H), 7.28–7.39 (m, 2 H, aryl-H), 8.12 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 8.2 ppm (–, Cpr-C), 11.2 (–, Cpr-C), 21.0 (C_{quat}, Cpr-C), 33.5 (+, CH₃), 51.5 (–, CH₂), 53.4 (+, CH), 56.8 (+, CH), 101.3 (–, CH₂), 108.3 (C_{quat}, aryl-C), 109.1 (+, aryl-C), 111.5 (+, aryl-C), 113.6 (+, aryl-C), 118.9 (C_{quat}, aryl-C), 120.0 (+, aryl-C), 122.4 (+, aryl-C), 122.5 (+, aryl-C), 123.9 (+, aryl-C), 130.4 (C_{quat}, aryl-C), 131.4 (C_{quat}, aryl-C), 136.5 (C_{quat}, aryl-C), 148.0 (C_{quat}, aryl-C), 148.2 (C_{quat}, aryl-C), 162.9 (C_{quat}, C=O), 163.0 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 415 (100) [M⁺], 315 (15), 289 (48). C₂₄H₂₁N₃O₄ (415.5): calcd. 415.1532 (correct HRMS).

cis-6'-(1,3-Benzodioxol-5-yl)-2'-methyl-2',3',6',7',12',12a'-hexahydrospiro[cyclopropane-1,12'-pyrazino[1',2':1,6]pyrido[3,4-b]indole]1',4'-dione (cis-13): A solution of *cis*-12 (226 mg, 500 μ mol) and methylamine (0.4 mL, 40% in H₂O) in EtOH (10 mL) was heated at 75 °C for 16 h. The volatiles were removed in vacuo, the residue was dissolved in CH₂Cl₂ (20 mL), washed with water (10 mL) and dried with MgSO₄. Evaporation of the solvents and chromatographic purification of the residue on 20 g of silica (1.5 × 20 cm, R_f = 0.40, pentane/Et₂O, 1:1) yielded 168 mg (81%) of *cis*-13 as a colorless solid, m.p. > 250 °C. IR (KBr): $\tilde{\nu}$ = 3245, 2890, 1668, 1489, 1465, 1332, 1040 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 1.10–1.16 (m, 2 H, Cpr-H), 1.36–1.40 (m, 1 H, Cpr-H), 1.72–1.78 (m, 1 H, Cpr-H), 3.01 (s, 3 H, CH₃), 3.85–4.20 (m, 2 H, CH₂), 4.52 (s, 1 H, CH), 5.22 (s, 1 H, CH), 5.98 (s, 2 H, CH₂), 6.71–6.84 (m, 3 H, aryl-H), 6.96–7.20 (m, 2 H, aryl-H), 7.26–7.38 (m, 2 H, aryl-H), 8.12 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 8.2 (–, Cpr-C), 11.2 (–, Cpr-C), 21.0 (C_{quat}, Cpr-C), 33.5 (+, CH₃), 51.5 (–, CH₂), 53.4 (+, CH), 56.8 (+, CH), 101.3 (–, CH₂), 108.3 (C_{quat}, aryl-C), 109.1 (+, aryl-C), 111.5 (+, aryl-C), 113.6 (+, aryl-C), 118.9 (C_{quat}, aryl-C), 120.0 (+, aryl-C), 122.4 (+, aryl-C), 122.5 (+, aryl-C), 123.9 (+, aryl-C), 130.4 (C_{quat}, aryl-C), 131.4 (C_{quat}, aryl-C), 136.5 (C_{quat}, aryl-C), 148.0 (C_{quat}, aryl-C), 148.2 (C_{quat}, aryl-C), 162.9 (C_{quat}, C=O), 163.0 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 416 (32), 415 (100) [M⁺], 315 (15), 289 (50), 274 (10). C₂₄H₂₁N₃O₄ (415.5): calcd. C 69.39, H 5.10, N 10.11; found C 69.12, H 5.09, N 9.91.

Methyl 1'-(2-Methylpropenyl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-(1H- β -carboline)]-3-carboxylate (10): 3-Methylcrotonaldehyde (prenal) (1.44 g, 17.2 mmol) was added to a solution of **7** (3.81 g, 15.6 mmol) in trimethyl orthoformate (70 mL) at 0 °C, and the mixture was stirred at this temperature for 12 h. Removal of the volatiles in vacuo yielded 4.80 g (15.5 mmol, 99%) of raw imine^[21] as a colorless solid, m.p. 152 °C. TFA (11.4 g, 100 mmol) was added to a solution of the raw imine (1.55 g, 5.00 mmol) in

CH₂Cl₂ (25 mL) at –30 °C, and the mixture was stirred at this temperature for 63 h. Then 2 N NaOH solution (60 mL) was added, the phases were separated, and the aqueous phase extracted with CH₂Cl₂ (3 × 50 mL). The combined organic phases were washed with brine (10 mL) and dried with MgSO₄. Evaporation of the solvents and chromatographic purification of the residue on 100 g of silica (4 × 30 cm, R_f = 0.48, Et₂O/EtOAc, 50:1) yielded 556 mg (36% yield) of **10** as a red oil. IR (film): $\tilde{\nu}$ = 3387 (NH), 3175, 3058, 2950, 1734 (C=O), 1457, 1376, 1258, 1194, 1110, 1016, 741 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.94–0.99 (m, 1 H, Cpr-H), 1.05–1.13 (m, 1 H, Cpr-H), 1.24–1.32 (m, 1 H, Cpr-H), 1.80 (s, 3 H, CH₃), 1.82–1.86 (m, 1 H, Cpr-H), 1.88 (s, 3 H, CH₃), 2.31–2.48 (br. s, 1 H, NH), 3.32 (s, 1 H, 3'-H), 3.63 (s, 3 H, OCH₃), 5.23 (d, ³J = 9.1 Hz, 1 H, 1'-H), 5.31 (d, ³J = 9.1 Hz, 1 H, 1''-H), 6.98 (m, 1 H, 6'-H), 7.06 (m, 1 H, 7'-H), 7.25 (d, ³J = 8.2 Hz, 1 H, 8'-H), 7.31 (d, ³J = 8.2 Hz, 1 H, 5'), 7.64–7.70 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.3 (–, Cpr-C), 14.1 (–, Cpr-C), 18.2 (+, CH₃), 19.8 (C_{quat}, Cpr-C), 25.8 (+, CH₃), 47.9 (+, C-1'), 51.6 (+, OCH₃), 63.3 (+, C-3'), 109.8 (C_{quat}, C-4a'), 111.0 (+, C-8'), 118.6 (+, C-5'*), 119.1 (+, C-7'*), 121.0 (+, C-6'), 124.5 (+, C-1''), 124.8 (C_{quat}, C-4b'), 135.2 (C_{quat}, C-9a'), 135.7 (C_{quat}, C-8a'), 137.3 (C_{quat}, C-2''), 173.1 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 310 (100) [M⁺], 295 (14), 251 (48) [M⁺ – CO₂Me], 223 (16), 195 (32), 180 (8), 167 (14). C₁₉H₂₂N₂O₂ (310.4): calcd. C 73.52, H 7.14, N 9.03; found C 73.54, H 6.90, N 8.89.

Methyl 2'-[1-(9H-Fluoren-9-ylmethoxycarbonyl)pyrrolidin-2-ylcarbonyl]-1'-(2-methylpropenyl)-2',3',4',9'-tetrahydrospiro[cyclopropane-1,4'-(1H- β -carboline)]-3-carboxylate (14a) and (14b): Fmoc-(S)-Pro–Cl (520 mg, 1.46 mmol) was added to a solution of **10** (301 mg, 970 μ mol) in CH₂Cl₂ (20 mL) at 20 °C. After 2 min, aqueous 1 N Na₂CO₃ (15 mL, 15 mmol) was added. After stirring for 4 h, the aqueous phase was extracted with CH₂Cl₂ (3 × 30 mL), the combined organic phases were washed with brine (10 mL) and dried with MgSO₄. Evaporation of the solvent and chromatographic purification of the residue on 35 g of silica (3 × 20 cm, pentane/EtOAc, 1:1) yielded 282 mg (46%) of **14a** (R_f = 0.52) as a yellow solid, m.p. 183 °C, and 266 mg (44%) of **14b** (R_f = 0.27) as a yellow solid, m.p. 174 °C.

(5a'R,12'S,14a'S)-1',2',3',5a',6',11',12',14a'-Octahydro-12'-(2-methyl-1-propenyl)-5'H,14'H-spiro[cyclopropane-1,6'-pyrrolidin-1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole]-5',14'-dione (15a): Piperidine (3 mL) was added to a solution of **14a** (260 mg, 413 μ mol) in CH₂Cl₂ (15 mL) at 20 °C and the mixture stirred for 1 h. Evaporation of the solvent and chromatographic purification of the residue on 35 g of silica (3 × 20 cm, R_f = 0.28, pentane/EtOAc, 1:1) yielded 107 mg (69%) of **15a** as a slightly yellow solid, m.p. 215 °C. [α]_D²⁰ = +164.6 (*c* = 0.35, CHCl₃). IR (KBr): $\tilde{\nu}$ = 3282 (NH), 3064, 2965, 2880, 1657 (C=O), 1440, 1332, 1296, 1261, 1148, 1077, 1016, 741 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.84–0.93 (m, 1 H, Cpr-H), 1.26–1.35 (m, 1 H, Cpr-H), 1.48–1.57 (m, 1 H, Cpr-H), 1.65–1.80 (m, 1 H, Cpr-H), 1.75 [s, 3 H, CH=C(CH₃)₂], 1.91 [s, 3 H, CH=C(CH₃)₂], 1.96–2.05 (m, 3 H, 1'-H, 2'-H), 2.41–2.46 (m, 1 H, 1'-H), 3.52–3.75 (m, 2 H, 3'-H), 4.14–4.20 (m, 1 H, 14a'-H), 4.77 (s, 1 H, 5a'-H), 5.49 [d, ³J = 8.6 Hz, 1 H, CH=C(CH₃)₂], 6.55 (d, ³J = 8.6 Hz, 1 H, 12'-H), 6.97–7.11 (m, 2 H, 8'-H, 9'-H), 7.23–7.31 (m, 2 H, 7'-H, 10'-H), 8.42 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 7.6 (–, Cpr-C), 11.3 (–, Cpr-C), 18.7 [+ , CH=C(CH₃)₂], 20.3 (C_{quat}, Cpr-C), 22.1 (–, C-2'), 25.8 [+ , CH=C(CH₃)₂], 29.7 (–, C-1'), 45.6 (–, C-3'), 47.3 (+, C-12'), 58.5 (+, C-5a'), 60.5 (+, C-14a'), 110.9 (C_{quat}, C-6a'), 111.3 (+, C-10'), 118.6 (+, C-7'), 119.6

(+, C-8'), 120.5 (+, C-9'), 121.7 [+ , CH=C(CH₃)₂], 124.0 (C_{quat}, C-6b'), 133.9 (C_{quat}, C-11a'), 136.2 [C_{quat}, CH=C(CH₃)₂], 139.7 (C_{quat}, C-10a'), 162.2 (C_{quat}, C-5'), 166.1 (C_{quat}, C-14') ppm. MS (70 eV): *m/z* (%) = 375 (100) [M⁺], 320 (8), 278 (14), 167 (11), 70 (16), 41 (16). C₂₃H₂₅N₃O₂ (375.5): calcd. 375.1947 (correct HRMS).

X-ray Crystal Structure Analysis of 15a: Formula C₂₃H₂₅N₃O₂, *M* = 375.5, colorless crystal, temperature 133(2) K, λ = 0.71073 Å, monoclinic, *P*₂₁, unit cell dimensions *a* = 8.4619(9) Å, *a* = 90°, *b* = 11.0894(10) Å, *b* = 98.896(8)°, *c* = 12.7990(13) Å, *c* = 90°, *V* = 1186.6(2) Å³, $\rho_{\text{calcd.}}$ = 1.170 g·cm⁻³. Absorption coefficient 0.183 mm⁻¹, *F*(000) 442. θ range for data collection 1.61–24.63°. Index ranges $-9 \leq h \leq 9$, $-12 \leq k \leq 12$, $-14 \leq l \leq 14$. Reflections collected/unique 5853/3371 [*R*(int) = 0.0407]. Observed reflections 3122 [*I* ≥ 2σ(*I*)]. Completeness to θ = 24.63–97.7. Refinement method: full-matrix least-squares on *F*². Data/restraints/parameters 3371/1/289. Goodness-of-fit on *F*² 1.068. Final *R* indices [*I* ≥ 2σ(*I*)], *R* = 0.0725, *wR*² = 0.2199; *R* indices (all data) *R* = 0.0772, *wR*² = 0.2260. Absolute structure parameter –0.2(3). Largest diff. peak and hole, 0.899 and –0.379 e·Å⁻³. CCDC-247926 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(5a',S,12'R,14a'S)-1',2',3',5a',6',11',12',14a'-Octahydro-12'-(2-methyl-1-propenyl)-5'H,14'H-spiro[cyclopropane-1,6'-pyrrolo-[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole]-5',14'-dione (15b): Piperidine (2 mL) was added to a solution of **14b** (184 mg, 292 μmol) in CH₂Cl₂ (10 mL) at 20 °C and the mixture was stirred for 2 h. Evaporation of the solvent and chromatographic purification of the residue on 25 g of silica (2.5 × 20 cm, *R*_f = 0.17, pentane/EtOAc, 1:1) yielded 67.4 mg (61%) of **15b** as a slightly yellow solid, m.p. 227 °C. [α]_D²⁰ = –5.0 (*c* = 0.30, CHCl₃). IR (KBr): $\tilde{\nu}$ = 3314 (NH), 2965, 2939, 1649 (C=O), 1455, 1303, 1145, 741 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): δ = 0.59–0.66 (m, 1 H, Cpr-H), 1.18–1.25 (m, 1 H, Cpr-H), 1.64–1.71 (m, 1 H, Cpr-H), 1.74 [s, 3 H, CH=C(CH₃)₂], 1.78–2.07 (m, 4 H, Cpr-H, 1'-H, 2'-H), 1.89 [s, 3 H, CH=C(CH₃)₂], 2.37–2.43 (m, 1 H, 1'-H), 3.24–3.33 (m, 1 H, 3'-H), 3.81–3.91 (m, 1 H, 3'-H), 4.05 (dd, ³*J* = 5.9, 10.8 Hz, 1 H, 14a'-H), 4.67 (s, 1 H, 5a'-H), 5.47 [d, ³*J* = 8.6 Hz, 1 H, CH=C(CH₃)₂], 6.64 (d, ³*J* = 8.6 Hz, 1 H, 12'-H), 6.97 (t, ³*J* = 7.9 Hz, 1 H, 8'-H), 7.05 (t, ³*J* = 7.9 Hz, 1 H, 9'-H), 7.23 (d, ³*J* = 7.9 Hz, 1 H, 10'-H), 7.33 (d, ³*J* = 7.9 Hz, 1 H, 7'-H), 8.42 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.1 (–, Cpr-C), 11.6 (–, Cpr-C), 18.8 [+ , CH=C(CH₃)₂], 21.7 (C_{quat}, Cpr-C), 22.2 (–, C-2'), 25.8 [+ , CH=C(CH₃)₂], 29.7 (–, C-1'), 44.3 (–, C-3'), 46.7 (+, C-12'), 58.6 (+, C-5a'), 59.4 (+, C-14a'), 111.2 (C_{quat}, C-6a'), 111.3 (+, C-10'), 118.8 (+, C-7'), 119.6 (+, C-8'), 121.0 (+, C-9'), 121.6 [+ , CH=C(CH₃)₂], 124.1 (C_{quat}, C-6b'), 133.1 (C_{quat}, C-11a'), 136.4 [C_{quat}, CH=C(CH₃)₂], 139.4 (C_{quat}, C-10a'), 161.9 (C_{quat}, C-5'), 164.3 (C_{quat}, C-14') ppm. MS (ESI, MeOH): *m/z* (%) = 398 (89) [M⁺ + Na], 773 (100) [2 M + Na⁺]. C₂₃H₂₅N₃O₂ (375.5): calcd. 375.1947 (correct HRMS).

Acknowledgments

This work was supported by Bayer CropScience AG and the Fonds der Chemischen Industrie. We are grateful to Celanese AG for the generous gift of chemicals. M. L. is indebted to the German National Merit Foundation (Studienstiftung des deutschen Volkes) for a student (2000–2002) and a doctoral fellowship (2002–2004). The authors are grateful to Dr. B. Knieriem, Göttingen, for his careful proofreading of the final manuscript.

- [1] [1a] P. López-Alvarado, S. García-Granda, C. Álvarez-Rúa, C. Avendaño, *Eur. J. Org. Chem.* **2002**, 1702–1707. [1b] P. M. T. Ferreira, H. L. S. Maia, L. S. Monteiro, J. Sacramento, J. Sebastião, *J. Chem. Soc., Perkin Trans. 1* **2000**, 3317–3324. [1c] J. H. Poupaert, J. Bukuru, A. Gozzo, *Monatsh. Chem.* **1999**, 130, 929–932. [1d] M.-F. Hsieh, P. D. Rao, C.-C. Liao, *Chem. Commun.* **1999**, 1441–1442. [1e] X.-L. Li, Y.-M. Wang, T. Matsuura, J.-B. Meng, *J. Heterocycl. Chem.* **1999**, 36, 697–701. [1f] S. Peng, E. Winterfeldt, *Liebigs Ann. Chem.* **1990**, 319–322. [1g] P. E. Harrington, M. A. Kerr, *Synlett* **1996**, 1047–1048. [1h] M. Bandini, P. G. Cozzi, M. Giacomini, P. Melchiorre, S. Selva, A. Umani-Ronchi, *J. Org. Chem.* **2002**, 67, 3700–3704.
- [2] [2a] C. Balsamini, G. Diamantini, A. Duranti, G. Spadoni, A. Tontini, *Synthesis* **1995**, 370–372. [2b] G. Spadoni, C. Balsamini, A. Bedini, E. Duranti, A. Tontini, *J. Heterocycl. Chem.* **1992**, 29, 305–309.
- [3] [3a] M.-Y. Chang, S.-T. Chen, N.-C. Chang, *Heterocycles* **2002**, 57, 2321–2334. [3b] K. Yamada, F. Yamada, M. Somei, *Heterocycles* **2002**, 57, 1231–1234. [3c] G. Galambos, P. Csókási, C. Szántay Jr., C. Szántay, *Liebigs Ann. Recl.* **1997**, 1969–1978. [3d] G. Galambos, P. Csókási, C. Szántay Jr., G. Czira, C. Szántay, *Heterocycles* **1994**, 38, 1727–1732. [3e] M. Toyota, K. Fukumoto, *J. Chem. Soc., Perkin Trans. 1* **1992**, 547–552. [3f] M. Somei, F. Yamada, H. Ohnishi, Y. Makita, M. Kuriki, *Heterocycles* **1987**, 26, 2823–2828. [3g] E. Ciganek, E. M. Schubert, *J. Org. Chem.* **1995**, 60, 4629–4634. [3h] A.-A. S. El-Ahl, *Synth. Commun.* **2000**, 30, 2223–2231.
- [4] For a review, see: E. D. Cox, J. M. Cook, *Chem. Rev.* **1995**, 95, 1797–1842.
- [5] J. Li, T. Wang, P. Yu, A. Peterson, R. Weber, D. Soerens, D. Grubisha, D. Bennett, J. M. Cook, *J. Am. Chem. Soc.* **1999**, 121, 6998–7010.
- [6] Natural demethoxyfunitremorgine C has an [α]_D³⁰ of 8.0 (*c* = 0.2, CHCl₃), cf. ref.[7c]
- [7] [7a] C.-B. Cui, H. Kakeya, G. Okada, R. Onose, M. Ubukata, I. Takahashi, K. Isono, H. Osada, *J. Antibiot.* **1995**, 48, 1382–1384. [7b] C.-B. Cui, H. Kakeya, G. Okada, R. Onose, H. Osada, *J. Antibiot.* **1996**, 49, 527–533. [7c] C.-B. Cui, H. Kakeya, H. Osada, *J. Antibiot.* **1996**, 49, 534–540. [7d] C.-B. Cui, H. Kakeya, H. Osada, *J. Antibiot.* **1996**, 49, 832–835. [7e] C.-B. Cui, H. Kakeya, H. Osada, *Tetrahedron* **1996**, 52, 12651–12666. [7f] C.-B. Cui, H. Kakeya, H. Osada, *Tetrahedron* **1997**, 53, 59–72.
- [8] S. K. Rabindran, H. He, M. Singh, E. Brown, K. I. Collins, T. Annable, L. M. Greenberger, *Cancer Res.* **1998**, 58, 5850–5858.
- [9] W. E. Pullman, S. J. Whitaker, A61 K31/4985, **2003**; Lilly Icos LLC. Pr.: WO2000US11129, **2000**.
- [10] [10a] M. Limbach, M. Es-Sayed, A. de Meijere, unpublished results. [10b] V. N. Belov, C. Funke, T. Labahn, M. Es-Sayed, A. de Meijere, *Eur. J. Org. Chem.* **1999**, 1345–1356.
- [11] A. Dougan, P. Grondin, C. Ruault, A.-C. Le Monnier de Gouville, H. Coste, J. Kirilovsky, F. Hyafil, R. Labaudinière, *J. Med. Chem.* **2003**, 46, 4525–4532.
- [12] A. Dougan, P. Grondin, C. Ruault, A.-C. Le Monnier de Gouville, H. Coste, J. M. Linget, J. Kirilovsky, F. Hyafil, R. Labaudinière, *J. Med. Chem.* **2003**, 46, 4533–4542.
- [13] [13a] P. D. Bailey, P. J. Cochrane, K. Lorenz, I. P. Collier, D. P. J. Pearson, G. M. Rosair, *Tetrahedron Lett.* **2001**, 42, 113–115. [13b] T. Gan, J. M. Cook, *Tetrahedron Lett.* **1997**, 38, 1301–1304. [13c] K. M. Depew, S. J. Danishefsky, N. Rosen, L. Sepp-Lorenzino, *J. Am. Chem. Soc.* **1996**, 118, 12463–12464.
- [14] This so-called Thorpe–Ingold effect had originally been attributed to an angle enlargement, see: [14a] R. M. Beesley, C. K. Ingold, J. F. Thorpe, *J. Chem. Soc.* **1915**, 107, 1080–1106. [14b] C. K. Ingold, *J. Chem. Soc.* **1921**, 119, 305. It was later shown that the major influence stems from the conformational preference of such a system, see: [14c] M. E. Jung, M. Kiankarimi, *J.*

- Org. Chem.* **1998**, 63, 2968–2974. ^[14d] M. E. Jung, J. Gervay, *J. Am. Chem. Soc.* **1991**, 113, 224–232.
- ^[15] The corresponding 2-amino-2-[1-(1*H*-indol-3-yl)cyclopropyl]-acetic acid has already been described, see: D. C. Horwell, M. J. McKiernan, S. Osborne, *Tetrahedron Lett.* **1998**, 39, 8729–8732.
- ^[16] Problems with the cyclization of prenalimines have also been observed by others, see: D. M. Harrison, R. B. Sharma, *Tetrahedron* **1993**, 49, 3165–3184.
- ^[17] ^[17a] P. D. Bailey, S. P. Hollinshead, N. R. Mc Lay, K. Morgan, S. J. Palmer, S. N. Prince, C. D. Reynolds, S. D. Wood, *J. Chem. Soc., Perkin Trans. 1* **1993**, 431–439. ^[17b] P. D. Bailey, M. H. Moore, K. M. Morgan, D. I. Smith, J. M. Vernon, *Tetrahedron Lett.* **1994**, 35, 3587–3588. ^[17c] H. Wang, A. Ganesan, *Tetrahedron Lett.* **1997**, 38, 4327–4328.
- ^[18] L. A. Carpino, B. J. Cohen, K. E. Stephens Jr., S. Y. Sadat-Aalae, J.-H. Tien, D. C. Langridge, *J. Org. Chem.* **1986**, 51, 3732–3734.
- ^[19] On the basis of the known absolute configuration of the employed (*S*)-proline and the assumption that it did not racemize during incorporation, this depicts the overall absolute configuration as well.
- ^[20] ^[20a] T. Liese, F. Seyed-Mahdavi, A. de Meijere, *Org. Synth.* **1990**, 69, 148–153. ^[20b] For an advanced synthesis of **4** see: M. Limbach, S. Dalai, A. de Meijere, *Adv. Synth. Catal.* **2004**, 346, 760–766.
- ^[21] In this case the imine was isolated before cyclization. Experimental data: methyl [1-(1*H*-indol-3-yl)cyclopropyl][(3-methylbut-2-enylidene)amino]acetate. IR (KBr): $\tilde{\nu}$ = 3129, 3087, 3012, 2920, 2881, 1745 (C=O), 1652, 1611, 1434, 1344, 1198, 1162, 1082, 739 cm⁻¹. ¹H NMR (CDCl₃): δ = 0.83–1.09 (m, 3 H, Cpr-H), 1.13–1.19 (m, 1 H, Cpr-H), 1.88 (s, 6 H, CH₃), 3.56 (s, 3 H, OCH₃), 3.80 (s, 1 H, 2-H), 6.11 (d, ³*J* = 9.4 Hz, 1 H, 2'-H), 7.06–7.17 (m, 3 H, 2''-H, 5''-H, 6''-H), 7.30 (d, ³*J* = 7.0 Hz, 1 H, 7''-H), 7.69 (d, ³*J* = 7.0 Hz, 1 H, 4''-H), 8.06 (d, ³*J* = 9.4 Hz, 1 H, 1'-H), 8.07–8.18 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃, DEPT): δ = 10.3 ppm (–, Cpr-C), 10.4 (–, Cpr-C), 18.7 (+, CH₃), 21.6 (C_{quat}, Cpr-C), 26.7 (+, CH₃), 51.8 (+, OCH₃), 79.7 (+, C-2), 111.2 (+, C-7''), 116.9 (C_{quat}, C-3''), 119.2 (+, C-4''*), 119.4 (+, C-6''*), 121.6 (+, C-5''), 125.2 (+, 2 C, C-2'', C-2'), 127.6 (C_{quat}, C-3a''), 135.9 (C_{quat}, C-7a''), 148.7 (C_{quat}, C-3'), 161.6 (C_{quat}, C-1'), 172.3 (C_{quat}, C=O) ppm. MS (70 eV): *m/z* (%) = 310 (12) [M⁺], 251 (100) [M⁺ – CO₂Me], 212 (6), 196 (12), 183 (4), 168 (13), 156 (30), 129 (15). C₁₉H₂₂N₂O₂ (310.4): calcd. C 73.52, H 7.14, N 9.03; found C 73.19, H 7.15, N 8.91.

Received September 2, 2004